Key Points
- CFO Felipe Duran purchased 24,835 shares of iBio on March 19 at an average price of $2.02 for a total of $50,166.70, raising his ownership to 35,974 shares — a 222.96% increase.
- iBio stock trades near $2.21 with a 50-day moving average of $2.37, a one‑year range of $0.56–$4.86 and a market cap of $76.33M; the company reported Q4 EPS of -$0.09, missing estimates.
- Analyst and institutional sentiment is mixed: the consensus rating is "Buy" with a $4.75 price target, while hedge funds and firms like State Street and Boothbay have recently increased or opened positions despite some sell ratings.
iBio, Inc. (NASDAQ:IBIO - Get Free Report) insider Martin Brenner bought 12,336 shares of the business's stock in a transaction on Thursday, March 19th. The shares were acquired at an average price of $2.02 per share, with a total value of $24,918.72. Following the transaction, the insider owned 30,652 shares of the company's stock, valued at $61,917.04. The trade was a 67.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
iBio Stock Up 5.7%
Shares of NASDAQ IBIO opened at $2.21 on Tuesday. The firm has a 50-day simple moving average of $2.37. The stock has a market capitalization of $76.33 million, a P/E ratio of -2.21 and a beta of 1.18. iBio, Inc. has a 12-month low of $0.56 and a 12-month high of $4.86.
iBio (NASDAQ:IBIO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01).
Analysts Set New Price Targets
Several research firms have weighed in on IBIO. Wall Street Zen downgraded iBio from a "hold" rating to a "sell" rating in a research report on Saturday. Weiss Ratings restated a "sell (d-)" rating on shares of iBio in a research report on Monday, December 29th. JonesTrading started coverage on iBio in a research note on Tuesday, March 3rd. They set a "buy" rating and a $7.00 price objective on the stock. Chardan Capital reissued a "buy" rating and issued a $5.00 target price on shares of iBio in a research note on Wednesday, March 18th. Finally, Lifesci Capital upgraded shares of iBio to a "strong-buy" rating in a report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $4.75.
Read Our Latest Research Report on iBio
Institutional Trading of iBio
Hedge funds and other institutional investors have recently bought and sold shares of the company. EcoR1 Capital LLC acquired a new position in iBio in the 4th quarter valued at $4,300,000. Affinity Asset Advisors LLC acquired a new stake in shares of iBio during the fourth quarter worth $3,970,000. Logos Global Management LP acquired a new stake in shares of iBio during the fourth quarter worth $3,860,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of iBio in the fourth quarter valued at $3,770,000. Finally, Balyasny Asset Management L.P. grew its position in shares of iBio by 10,440.2% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,096,179 shares of the company's stock valued at $2,116,000 after purchasing an additional 1,085,779 shares during the period. 7.90% of the stock is owned by hedge funds and other institutional investors.
About iBio
(
Get Free Report)
iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
